WALTHAM, Mass and DUBLIN, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered therapies targeting cytokine pathways, today announced that CEO Caroline Loew, Ph.D., will present at the TD Cowen 45th Annual Health Care Conference on March 4, 2025 and 3:10 p.m. ET. A live webcast of the presentation will be available at https://ir.muraloncology.com/events-and-presentations. A replay of the webcast will be archived and available following the event.

VICI Properties, owning 93 properties, generates $1.2 billion in rent from Caesars, and has diversified into experiential sectors like bowling and Chelsea Piers. VICI's strong balance sheet includes $2.9 billion liquidity and $17.1 billion debt, with a net debt-to-EBITDA ratio of 5.4x and BBB-/BBB-/Ba1 credit ratings. VICI has consistently grown AFFO per share by 7.2% CAGR since 2018 and dividends by 8% annually, with expected growth of 2%-5% in coming years.

EDEN PRAIRIE, Minn., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Winnebago Industries, Inc. (NYSE: WGO) (the “Company”), a leading manufacturer of outdoor recreation products, today announced early results of its previously announced cash tender offer (the “Tender Offer”) to purchase its 6.250% Senior Secured Notes due 2028 (CUSIP No.

SAN FRANCISCO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced the appointment of Shawnte M. Mitchell, J.D., as Chief Legal Officer and Corporate Secretary.

WALTHAM, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in a fireside chat at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference on Tuesday, February 25, 2025 at 10:00 a.m. Eastern Time.

NEW YORK CITY, NY / ACCESS Newswire / February 18, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Merck & Co., Inc. ("Merck" or "the Company") (NYSE:MRK) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Merck securities between February 3, 2022 and February 3, 2025, both dates inclusive (the "Class Period").

NEW YORK CITY, NY / ACCESS Newswire / February 18, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Venture Global, Inc. ("Venture Global" or "the Company") (NYSE:VG) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Venture Global securities pursuant to the registration statement and prospectus issued in connection with the Company's January 24, 2025 initial public offering ("IPO").

NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the standard-of-care head and neck cancer drugs pembrolizumab (Keytruda) or cetuximab (Erbitux)

ADDISON, Texas, Feb. 18, 2025 (GLOBE NEWSWIRE) -- CECO Environmental Corp. (Nasdaq: CECO), a leading environmentally focused, diversified industrial company whose solutions protect people, the environment and industrial equipment, today announced that it will report its fourth quarter 2024 financial results on February 25, 2025, premarket. The Company will also host its earnings call starting at 8:30 a.m. Eastern Time (7:30 a.m. CT). The Company's financial results and presentation will be posted on its website at www.cecoenviro.com.

A Vote "FOR" Barington's Nominees is a Vote in Favor of the Relevant Skills, Board Experience, Independent Perspectives and Fierce Commitment to Shareholders Required to Help Drive Good Governance and Long-Term Value Creation at Matthews Warns Shareholders NOT to Be Misled by Matthews' Blatant Last-Minute Attempts to Placate Shareholders Days Before the 2025 Annual Meeting of Shareholders Reaffirms that the Incumbent Board Has Overseen 18 Years of Underperformance, Unacceptable Capital Allocation and Operating Execution, and Poor Corporate Governance Strongly Encourages Shareholders to Follow the Recommendations of Leading Independent Proxy Advisory Firms ISS, Glass Lewis, and Egan-Jones and Voting "FOR" ALL …

SIMOS Solutions and Centerline Drivers also receive awards for dedication to client satisfaction TACOMA, Wash. , Feb. 18, 2025 /PRNewswire/ -- TrueBlue (NYSE: TBI), a leading provider of specialized workforce solutions, is pleased to announce that its brand Staff Management | SMX has received the distinction as a 10-Year Diamond award winner by the ClearlyRated 2025 Best of Staffing Awards®.

VANCOUVER, BC , Feb. 18, 2025 /PRNewswire/ - New Found Gold Corp. ("New Found" or the "Company") (TSXV: NFG) (NYSE-A: NFGC) is pleased to announce the appointment of Dr. Fiona Childe (Ph.D., P.Geo.) as Vice President, Communications and Corporate Development, Dr. Jared Saunders (Ph.D.

Recent clinical data presentations in these two hard-to-treat GI cancers, coupled with strong efficacy signals in breast cancer, demonstrate the potential of pelareorep across very different tumor types SAN DIEGO and CALGARY, AB , Feb. 18, 2025 /PRNewswire/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, continues to make good progress in 2025 with key regulatory and clinical advancements, reinforcing pelareorep's potential in hard-to-treat cancers. Oncolytics is pleased to highlight two significant developments for its immunotherapy, pelareorep: the safety and regulatory clearance to advance enrollment in its pancreatic cancer study …

PALM BEACH GARDENS, Fla. , Feb. 18, 2025 /PRNewswire/ -- Carrier Global Corporation (NYSE: CARR), global leader in intelligent climate and energy solutions, today announced that its venture group, Carrier Ventures, is leading an investment and technology partnership with ZutaCore®, a disruptive innovator of two-phase direct-to-chip liquid cooling technology for data centers.

Fiscal year 2024 revenue of $944M, up 19% YoY Q4 revenue growth of 18% year-over-year Q4 net income of $19.1 million and non-GAAP net income of $52.1 million Fiscal year 2024 net loss $19.1 million, 62.7% improvement YoY Fiscal year 2024 adjusted EBITDA of $383M, up 15% YoY Q4 net income margin of 8%; adjusted EBITDA margin of 41% LEHI, Utah and LOUISVILLE, Ky., Feb. 18, 2025 /PRNewswire/ -- Waystar Holding Corp. (Nasdaq: WAY), a provider of leading healthcare payment software, today reported results for the fourth quarter and full year ended December 31, 2024.

Gross margins improved to 29.2% led by a growing independent power producer ("IPP") revenue base. This news release constitutes a "designated news release" for the purposes of the Company's prospectus supplement dated May 23, 2024, to its short form base shelf prospectus dated May 2, 2023.

OMAHA, Neb.--(BUSINESS WIRE)--Valmont® Industries, Inc. (NYSE: VMI), a global leader that provides products and solutions to support vital infrastructure and advance agricultural productivity, today reported financial results for the fourth quarter and fiscal year ended December 28, 2024. President and Chief Executive Officer Avner M. Applbaum commented, “The fourth quarter capped off an outstanding year for Valmont as we continued executing our strategy. Both our Infrastructure and Agriculture.

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that Gilead's time-limited exclusive option rights to casdatifan have expired. In addition, Arcus has announced the pricing of a $150 million common stock offering, which is subject to customary closing conditions and includes participation from new and existing.

NVDA's Q4 2025 earnings report on February 26 could drive volatility, with high implied volatility suggesting significant price swings. NVDY, a covered call ETF on NVDA, offers a high yield but has underperformed the S&P 500 by 10 percentage points. Despite recent underperformance, I maintain a buy rating on NVDY due to favorable technical conditions and high implied volatility.

Shares of Southwest Airlines (LUV) rose in premarket trading Tuesday after the carrier said it plans to cut 15% of its corporate workforce, eliminating about 1,750 jobs in the first large layoffs in its 53-year history.